Sacubitril/valsartan improves both functional and echocardiographic parameters in patients with chronic heart failure with reduced ejection fraction.
Eugenio Roberto CosentinoDaniela Degli EspostiRinaldo MiceliCrescenzio BentivengaMatteo LandolfoArrigo Francesco Giuseppe CiceroEmanuela BerardiLuca SpinardiGianluigi MagriVittorio DugatoClaudio BorghiPublished in: Current medical research and opinion (2020)
Based on our real-life experience, in HFrEF patients with NYHA class II-III, the new angiotensin receptor-neprilysin inhibitor (ARNi) sacubitril/valsartan was effective in improving HF management, both from the clinical and the echocardiographic perspective.